The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD
Research Funding - Lilly (Inst); MSD (Inst)
The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
 
Hiromi Watanabe
No Relationships to Disclose
 
Toshio Kubo
Speakers' Bureau - Kyowa Hakko Kirin; Taiho Pharmaceutical
 
Kiichiro Ninomiya
Honoraria - Boehringer Ingelheim; Chugai Pharma
 
Kenichiro Kudo
No Relationships to Disclose
 
Daisuke Minami
No Relationships to Disclose
 
Etsuko Murakami
No Relationships to Disclose
 
Nobuaki Ochi
No Relationships to Disclose
 
Takashi Ninomiya
Honoraria - Boehringer Ingelheim; Chugai Pharma
 
Daijiro Harada
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Yakult Pharmaceutical
 
Masayuki Yasugi
No Relationships to Disclose
 
Eiki Ichihara
No Relationships to Disclose
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Lilly Japan; Novartis
 
Keiichi Fujiwara
No Relationships to Disclose
 
Katsuyuki Hotta
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Oncology (Inst); AstraZeneca (I); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (I)
 
Masahiro Tabata
No Relationships to Disclose
 
Yoshinobu Maeda
Honoraria - Asahi Kasei; Astellas Oncology; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Yakult Pharmaceutical
Research Funding - Asahi Kasei (Inst); Astellas Oncology (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Meiji Seika Kaisha (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Yakult Pharmaceutical (Inst)
 
Katsuyuki Kiura
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)